Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 71, Issue 12, Pages 3043-3056Publisher
SPRINGER
DOI: 10.1007/s00262-022-03219-z
Keywords
NK cells; CD73; Tumor microenvironment; Immunometabolism; Adenosine
Categories
Funding
- V Foundation for Cancer Research [D2019-039]
- Lilly Graduate Fellowship
- Migliaccio/Pfizer Graduate Fellowship
- McKeehan Graduate Fellowship
- Biological Evaluation Shared Resource and the Flow Cytometry Shared Resource
- Purdue Center for Cancer Research, NIH [P30 CA023168]
- IU Simon Cancer Center NIH [P30 CA082709]
- Walther Cancer Foundation
Ask authors/readers for more resources
The production of adenosine by CD73 on cancer cells in the tumor microenvironment is an immunosuppressive mechanism. NK cells have limited upregulation of CD73 and it is influenced by cancer type and environment. CD73 overexpression on NK cells responds to the level of CD73 on cancer cells and is enhanced in hypoxia. NK cells in glioblastoma patients show variable CD73 expression and other functional changes.
The production of adenosine by CD73 on cancer cells in the tumor microenvironment is a recognized immunosuppressive mechanism contributing to immune evasion in many solid tumors. While NK cells have been purported to overexpress CD73 under certain conditions, this phenomenon has remained elusive and unclear. We have found that while NK cells are able to upregulate expression of CD73 on their surface when exposed to CD73(+) cancer cells, this upregulation is not universal, nor is it often substantial. Rather, our data point to the extent of CD73 expression on NK cells to be both cancer-specific and environmentally-driven, and largely limited in intensity. We found that NK cell overexpression of CD73 responds to the level of CD73 on cancer cells and is enhanced in hypoxia. Interestingly, human CD73(+) NK cells appear hyperfunctional in vitro compared to CD73(-) NK cells, suggesting that CD73 expression could be a bystander of NK cell activation. In addition, glioblastoma patient data show that tumor-infiltrating NK cells express CD73 variably, depending on donor, and present lower expression of CD16, alongside patient-specific changes in CEACAM1, CXCR3 and TIM-3, suggesting some functional changes in NK cell responses associated with expression of CD73 on NK cells in vivo. Taken together, our study is the first to show that while NK cells are largely resistant to the upregulation of CD73, CD73 expression is inducible on NK cells in response to CD73 on cancer cells, and these cells are associated with distinct functional signatures.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available